Asian Treat to Target Lantus Study: A Randomized, Multicentre, Multinational, Open-Label, Parallel-Group, 24-Week Phase IV Study Evaluating the Effectiveness and Safety of Physician Versus Patient-led Initiation and Titration of Insulin Glargine in Type 2 Diabetes Mellitus.

Trial Profile

Asian Treat to Target Lantus Study: A Randomized, Multicentre, Multinational, Open-Label, Parallel-Group, 24-Week Phase IV Study Evaluating the Effectiveness and Safety of Physician Versus Patient-led Initiation and Titration of Insulin Glargine in Type 2 Diabetes Mellitus.

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jun 2018

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms ATLAS
  • Sponsors Sanofi
  • Most Recent Events

    • 26 Jun 2018 Results comparing data from TAKE-CONTROL, AT.LANTUS, and ATLAS Studies presented at the 78th Annual Scientific Sessions of the American Diabetes Association
    • 01 Apr 2018 Results of pooled analysis of Asian patients included in this and other six trials assessing the impact of patient baseline covariates on the required dose of basal insulin and treatment response for the improved management of Asian patients with type 2 diabetes published in the Diabetes Therapy
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top